Clinical course of haemodialysis patients with malignancies and dose-adjusted chemotherapy

Nephrology Dialysis Transplantation

Volumn 20, Issue , 2005, Pages 1187-1191

  Boesler, Benjamin ^a   Czock, David ^a   Keller, Frieder ^a,b   Griesshammer, Martin ^a   Seufferlein, Thomas ^a   Karges, Wolfram ^a   Rasche, Franz Maximilian ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Chemotherapy; Dose adjustment; Haemodialysis; Malignancies; Nephropharmacology; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IDARUBICIN; MELPHALAN; METOCLOPRAMIDE; MITOXANTRONE; NAVELBINE; ONDANSETRON; PROCARBAZINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BREAST CANCER; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL PROTOCOL; COLON CARCINOMA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HEMATOLOGIC MALIGNANCY; HEMODIALYSIS; HODGKIN DISEASE; HUMAN; INFECTION; KAPLAN MEIER METHOD; KIDNEY FAILURE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG TOXICITY; MALE; MALIGNANT NEOPLASTIC DISEASE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; NEUROTOXICITY; PANCREAS CARCINOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOLID TUMOR; VOMITING;

ANTINEOPLASTIC AGENTS; COMORBIDITY; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MULTIPLE MYELOMA; NEOPLASMS; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 20844440735     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh807     Document Type: Article

References (17)

1. Palestini M, Lucandri G, Sterpetti A, Izzo L, Orefici F, Cavallaro A. Cancer surveillance in patients receiving long-term hemodialysis. Anticancer Res 2002; 22: 1305-1310
2. Maisonneuve P, Agodoa L, Gellert R et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354: 93-99
3. Cengiz K. Increased incidence of neoplasia in chronic renal failure (20-year experience). Int Urol Nephrol 2002; 33: 121-126
4. Sarnak MJ, Jaber BL. Pulmonary infectious mortality among patients with end-stage renal disease. Chest 2001; 120: 1883-1887
5. Watanabe R, Takiguchi Y, Moriya T et al. Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer. Br J Cancer 2003; 88: 25-30
6. Kurisu A, Hata T, Owada A. Full-dose chemotherapy for esophageal cancer patient under hemodialysis. Nephron 2002; 92: 960
7. Fish RG, Shelley MD, Griffiths H, Mason M, Adams M, James K. A dosing scheme for carboplatin in adult cancer patients based upon pre-infusion renal function and platelet count. Anticancer Drugs 1994; 5: 527-532
8. Chatelut E, Rostaing L, Gualano V et al. Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency. Nephron 1994; 66: 157-161
9. Dettli L. Drug dosage in renal disease. Clin Pharmacokinet 1976; 1: 126-134
10. Giusti DL, Hayton WL. Dosage regimen adjustments in renal impairment. Drug Intel Clin Pharm 1973; 7: 382-387
11. Czock D, Boesler B, Rasche M, Lukas R, Keller F. [Suggestions for dose adjustment in renal faillure patients.] Nieren-Hochdruckkrh 2003; 32: 74-80.
12. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998; 338: 499-505
13. Inoue A, Saijo Y, Kikuchi T et al. Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis. Ann Oncol 2004; 15: 51-54
14. Lesar TS, Rotschafer JC, Strand LM, Solem LD, Zaske DE. Gentamicin dosing errors with four commonly used nomograms. J Am Med Assoc 1982; 248: 1190-1193
15. Irish AB, Winearls CG, Littlewood T. Presentation and survival of patients with severe renal failure and myeloma. Q J Med 1997; 90: 773-780
16. Casserly LF, Fadia A, Sanchorawala V et al. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Kidney Int 2003; 63: 1051-1057
17. Royer B, Arnulf B, Martinez F et al. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int 2004; 65: 642-648